Download First And Second Generation Antipsychotics For Children And Young Adults full books in PDF, epub, and Kindle. Read online First And Second Generation Antipsychotics For Children And Young Adults ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Download or read book First- and Second-Generation Antipsychotics for Children and Young Adults written by and published by . This book was released on 2012 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update written by and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : U. S. Department of Health and Human Services
Publisher : Createspace Independent Pub
ISBN 13 : 9781484133873
Total Pages : 402 pages
Book Rating : 4.70/5 ( download)
Download or read book First- and Second-Generation Antipsychotics for Children and Young Adults written by U. S. Department of Health and Human Services and published by Createspace Independent Pub. This book was released on 2013-04-16 with total page 402 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antipsychotic medications are widely used to treat several psychiatric disorders and are commonly categorized into two classes. First-generation antipsychotics (FGAs), also known as typical antipsychotics, were developed in the 1950s. Although they are used to treat psychotic symptoms, they are associated with various side effects including extrapyramidal symptoms, which are movement disorders characterized by repetitive, involuntary muscle movements, restlessness, or an inability to initiate movement. Other common side effects are dry mouth and sedation. Neuroleptic malignant syndrome and tardive dyskinesia are rare but serious side effects. Second-generation antipsychotics (SGAs), also known as atypical antipsychotics, emerged in the 1980s. They are generally thought to have a lower risk of motor side effects. However, SGAs are associated with a higher risk of weight gain, elevated lipid and prolactin levels, and development of type 2 diabetes. Use of antipsychotics for children and adolescents has increased during the past 20 years. Prescribing antipsychotics to the pediatric population is controversial because there are few high quality and longitudinal studies on which to base clinical practice recommendations. For the majority of antipsychotic drugs, approved indications in the U.S. are restricted to the treatment of childhood schizophrenia and bipolar disorders. In 2006, the U.S. Food and Drug Administration (FDA) approved risperidone and aripiprazole for the treatment of irritability associated with autism. Off-label prescriptions are given to younger children for behavioral symptoms that are related to diagnosable conditions. In general, the choice of medication in children and adolescents is often driven by side-effect profiles that may affect growth and development, medication adherence and persistence, as well as other important domains such as school performance and health-related quality of life. This review provides a comprehensive synthesis of the evidence examining the benefits and harms associated with the use of FDA-approved FGAs and SGAs in children, adolescents, and young adults less than or equal to 24 years of age. The Key Questions are as follows: 1. What is the comparative efficacy or effectiveness of FGAs and SGAs for treating disorder- or illness-specific and nonspecific symptoms in children, youth, and young adults for the following disorders or illnesses? Pervasive developmental disorders, including autistic disorder, Rett's disorder, childhood disintegrative disorder, Asperger's disorder, and pervasive developmental disorder not otherwise specified; ADHD and disruptive behavior disorders, including conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified; Pediatric bipolar disorder, including manic or depressive phases, rapid cycling, and mixed states; Schizophrenia and schizophrenia-related psychoses, including schizoaffective disorder and drug-induced psychosis; Obsessive-compulsive disorder; Post-traumatic stress disorder; Anorexia nervosa; Tourette syndrome; Behavioral issues, including aggression, agitation, anxiety, behavioral dyscontrol, irritability, mood lability, self-injurious behaviors, and sleep disorders. 2. Do FGAs and SGAs differ in medication-associated adverse events when used in children, youth, and young adults? 3. Do FGAs and SGAs differ in other short- and long-term outcomes when used in children, youth, and young adults? 4. Do the effectiveness and risks of FGAs and SGAs vary in differing subpopulations including: Sex? Age group (less than 6 years [preschool], 6–12 years [preadolescent], 13–18 years [adolescent], 19–24 years [young adult])? Race? Comorbidities, including substance abuse and ADHD? Cotreatment versus monotherapy? First-episode psychosis versus treatment in context of history of prior episodes (related to schizophrenia)? Duration of illness? Treatment naïve versus history of previous antipsychotics use?
Author : U. S. Department of Health and Human Services
Publisher : Createspace Independent Pub
ISBN 13 : 9781484974346
Total Pages : 70 pages
Book Rating : 4.44/5 ( download)
Download or read book Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults written by U. S. Department of Health and Human Services and published by Createspace Independent Pub. This book was released on 2013-05-14 with total page 70 pages. Available in PDF, EPUB and Kindle. Book excerpt: The purpose of this future research needs (FRN) report is to develop a list of stakeholders' research needs related to the comparative effectiveness of first- and second-generation antipsychotics (FGAs and SGAs) in pediatric and young adult populations. This FRN report is based on an Agency for Healthcare Research and Quality (AHRQ) comparative effectiveness review (CER) titled “First- and Second-Generation Antipsychotics for Children and Young Adults.” We reviewed the CER in draft form. The purpose of the CER was to review and synthesize the evidence regarding the benefits and harms of FGAs and SGAs for the treatment of various psychiatric and behavioral conditions in children and young adults 24 years of age or younger. FGAs and SGAs are commonly categorized into two classes. FGAs, also known as typical antipsychotics, were developed in the 1950s. FGAs are used to treat psychotic symptoms such as auditory and visual hallucinations and delusions through several proposed mechanisms, including through the blockade of dopamine neuro-receptors. FGAs are associated with various adverse effects. These side effects include extra-pyramidal symptoms (EPS). EPS is a group of movement disorders, including acute dystonic reactions (severe spasms of various muscle groups), akathisia (a feeling of motor restlessness), pseudo-parkinsonism (medication-induced motor slowness and rigidity), and tardive dyskinesia (repetitive low amplitude movements, most often of facial muscles, insidious and chronic in nature). The most severe antipsychotic-associated potential side effect is neuroleptic malignant syndrome (NMS), characterized by hyperthermia, rigidity, rhabdomyolysis, renal failure, delirium, cardiovascular instability, and death. SGAs, also known as atypical antipsychotics, emerged in the 1980s. SGAs are generally thought to have a lower risk of EPS. The risk of NMS is rare for both medication classes, and researchers are uncertain about whether there is an intra-class risk difference for NMS. However, SGAs are associated with a higher risk of a range of metabolic side effects, including weight gain; dyslipidemia; insulin resistance; the development of type 2 diabetes; and, rarely, hyperglycemic coma. The review1 was prompted by the observation that the use of antipsychotics, particularly SGAs, for children and adolescents has increased markedly during the past 20 years. Prescribing antipsychotics to the pediatric population is controversial because of a relative lack of high-quality and longitudinal studies on which to base clinical practice recommendations. For the majority of antipsychotic drugs, approved indications in the United States are restricted to the treatment of childhood schizophrenia and bipolar disorders. The U.S. Food and Drug Administration (FDA) approved risperidone in 2006 and aripiprazole in 2009 for the treatment of irritability associated with autism. Off-label prescriptions are given to younger children for a range of indications including behavioral symptoms (e.g., aggression) that are related to diagnosable conditions (e.g., attention deficit hyperactivity disorder [ADHD]). In general, much prescribing of SGAs for children and adolescents does not appear to be guided by evidence of clinical benefit or risk of harms.
Author : Stephen M. Stahl
Publisher : Cambridge University Press
ISBN 13 : 1108446566
Total Pages : 525 pages
Book Rating : 4.63/5 ( download)
Download or read book Prescriber's Guide Children and Adolescents written by Stephen M. Stahl and published by Cambridge University Press. This book was released on 2018-10-18 with total page 525 pages. Available in PDF, EPUB and Kindle. Book excerpt: Presents a user-friendly step-by-step manual on the psychotropic drugs prescribed for children and adolescents by clinicians and nurse practitioners.
Author : National Collaborating Centre for Mental Health (Great Britain)
Publisher : RCPsych Publications
ISBN 13 : 9781908020604
Total Pages : 512 pages
Book Rating : 4.01/5 ( download)
Download or read book Psychosis and Schizophrenia in Children and Young People written by National Collaborating Centre for Mental Health (Great Britain) and published by RCPsych Publications. This book was released on 2013 with total page 512 pages. Available in PDF, EPUB and Kindle. Book excerpt: These guidelines from NICE set out clear recommendations, based on the best available evidence, for health care professionals on how to work with and implement physical, psychological and service-level interventions for people with various mental health conditions.The book contains the full guidelines that cannot be obtained in print anywhere else. It brings together all of the evidence that led to the recommendations made, detailed explanations of the methodology behind their preparation, plus an overview of the condition covering detection, diagnosis and assessment, and the full range of treatment and care approaches. There is a worse prognosis for psychosis and schizophrenia when onset is in childhood or adolescence, and this new NICE guideline puts much-needed emphasis on early recognition and assessment of possible psychotic symptoms. For the one-third of children and young people who go on to experience severe impairment as a result of psychosis or schizophrenia the guideline also offers comprehensive advice from assessment and treatment of the first episode through to promoting recovery.This guideline reviews the evidence for recognition and management of psychosis and schizophrenia in children and young people across the care pathway, encompassing access to and delivery of services, experience of care, recognition and management of at-risk mental states, psychological and pharmacological interventions, and improving cognition and enhancing engagement with education and employment.
Author : Stephen M. Strakowski
Publisher : Oxford University Press, USA
ISBN 13 : 0199985359
Total Pages : 401 pages
Book Rating : 4.57/5 ( download)
Download or read book Bipolar Disorder in Youth written by Stephen M. Strakowski and published by Oxford University Press, USA. This book was released on 2014-10-29 with total page 401 pages. Available in PDF, EPUB and Kindle. Book excerpt: 'Bipolar Disorder in Youth' provides a timely, focused review of the diagnosis, treatment, and neurobiology of bipolar disorder in youth. The editors and authors of each chapter represent international leaders in the care and study of this population. This book is the most comprehensive volume available discussing this important population and is a 'must' for the libraries of clinicians and scientists working with bipolar children and adolescents.
Author : Peter Haddad
Publisher : Oxford University Press
ISBN 13 : 0191045780
Total Pages : 320 pages
Book Rating : 4.83/5 ( download)
Download or read book Antipsychotic Long-acting Injections written by Peter Haddad and published by Oxford University Press. This book was released on 2016-05-10 with total page 320 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antipsychotic Long-acting Injections (LAIs) were introduced in the 1960s to improve treatment adherence in schizophrenia. Subsequently, first-generation antipsychotic LAIs became widely used in many countries. Since the initial publication of Antipsychotic Long-acting Injections in 2010, new trial data have been published on long-acting injection (LAI) preparations of the drugs Risperidone, Paliperidone, and Olanzapine. Furthermore, a new LAI preparation of the drug Aripiprazole has recently been approved for clinical use in the United States and is likely to be approved in Europe soon. The second edition of this successful book has been fully updated to include this new data, with reference to both observational studies and randomized controlled trials, as well as other new developments in the clinical use of antipsychotic LAIs. New chapters have been added covering the comparison between oral and injectable antipsychotics, Olanzapine LAI, Aripiprazole LAI, and the practicalities of organizing a specialized clinic for long-acting injectable antipsychotics. Existing chapters have also been thoroughly updated to take into account the most recently published research. Antipsychotic Long-acting Injections, Second edition brings together clinical and research findings on LAIs in a comprehensive volume, with chapters written by international experts.
Author : Katherine J. Aitchison
Publisher : CRC Press
ISBN 13 : 0429524145
Total Pages : 152 pages
Book Rating : 4.41/5 ( download)
Download or read book First Episode Psychosis written by Katherine J. Aitchison and published by CRC Press. This book was released on 2022-03-26 with total page 152 pages. Available in PDF, EPUB and Kindle. Book excerpt: The new edition of this popular handbook has been thoroughly updated to include the latest data concerning treatment of first-episode patients. Drawing from their experience, the authors discuss the presentation and assessment of the first psychotic episode and review the appropriate use of antipsychotic agents and psychosocial approaches in effective management. This is an authoritative text written by a team of highly respected authors for psychiatrists, neurologists, primary care practitioners and health care professional working in psychiatry. Drawing from their experience, the presentation and assessment of the first psychotic episode are discussed, details regarding antipsychotic drugs and their appropriate use are reviewed and psychosocial approaches are examined. The resulting book offers a concise and valuable guide to those wishing to review the latest proposals for the treatment of first-episode psychosis supported by up-to-date references, in a single publication.
Author : Christopher Gillberg
Publisher : Cambridge University Press
ISBN 13 : 9781139447416
Total Pages : 776 pages
Book Rating : 4.16/5 ( download)
Download or read book A Clinician's Handbook of Child and Adolescent Psychiatry written by Christopher Gillberg and published by Cambridge University Press. This book was released on 2006-02-09 with total page 776 pages. Available in PDF, EPUB and Kindle. Book excerpt: Originally published in 2006, this authoritative clinical handbook provides a detailed overview of the main disorders encountered by child and adolescent psychiatrists in clinical practice, ranging from eating, sleep and affective disorders to substance abuse, gender identity disorder and sexual abuse. The approach is evidence based and emphasis is on good clinical practice and quality control of patient care. In contrast to other books in the field, the authors' intention is not to cover exhaustively all the relevant science, but rather to present in condensed form any research findings that are significant for clinical practice. For coherence, each chapter is constructed in the same way: introduction, definition and classification, epidemiology, the clinical picture, aetiology, treatment and outcome. The disorders covered are based on the ICD- 10 and DSM-IV classifications, and appendices include documents for assessment of intervention planning and evaluation.
